Cargando…
PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429377/ http://dx.doi.org/10.1097/01.HS9.0000850968.59423.24 |
| _version_ | 1784779422662918144 |
|---|---|
| author | Vij, R. Schade, H. Trudel, S. Chang, A. C. Huang, J. Samineni, D. Sumiyoshi, T. Tsai, J. Wong, T. Harrison, S. J. |
| author_facet | Vij, R. Schade, H. Trudel, S. Chang, A. C. Huang, J. Samineni, D. Sumiyoshi, T. Tsai, J. Wong, T. Harrison, S. J. |
| author_sort | Vij, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429377 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94293772022-08-31 PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA Vij, R. Schade, H. Trudel, S. Chang, A. C. Huang, J. Samineni, D. Sumiyoshi, T. Tsai, J. Wong, T. Harrison, S. J. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429377/ http://dx.doi.org/10.1097/01.HS9.0000850968.59423.24 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Vij, R. Schade, H. Trudel, S. Chang, A. C. Huang, J. Samineni, D. Sumiyoshi, T. Tsai, J. Wong, T. Harrison, S. J. PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title | PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2034: camma 1: a multicenter phase ib trial evaluating the safety, pharmacokinetics and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429377/ http://dx.doi.org/10.1097/01.HS9.0000850968.59423.24 |
| work_keys_str_mv | AT vijr pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT schadeh pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT trudels pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT changac pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT huangj pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT saminenid pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT sumiyoshit pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT tsaij pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT wongt pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma AT harrisonsj pb2034camma1amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofcevostamabcontainingregimensinpatientswithrelapsedorrefractorymultiplemyeloma |